- Home
- PSF vs CMPX Comparison
PSF vs CMPX Comparison
Compare PSF & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSF
- CMPX
- Stock Information
- Founded
- PSF 2010
- CMPX 2014
- Country
- PSF United States
- CMPX United States
- Employees
- PSF N/A
- CMPX N/A
- Industry
- PSF Investment Managers
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- PSF Finance
- CMPX Health Care
- Exchange
- PSF Nasdaq
- CMPX Nasdaq
- Market Cap
- PSF 235.2M
- CMPX 229.5M
- IPO Year
- PSF N/A
- CMPX N/A
- Fundamental
- Price
- PSF $19.53
- CMPX $2.10
- Analyst Decision
- PSF
- CMPX Strong Buy
- Analyst Count
- PSF 0
- CMPX 8
- Target Price
- PSF N/A
- CMPX $13.13
- AVG Volume (30 Days)
- PSF 25.0K
- CMPX 804.2K
- Earning Date
- PSF 01-01-0001
- CMPX 05-08-2025
- Dividend Yield
- PSF 7.69%
- CMPX N/A
- EPS Growth
- PSF N/A
- CMPX N/A
- EPS
- PSF N/A
- CMPX N/A
- Revenue
- PSF N/A
- CMPX $850,000.00
- Revenue This Year
- PSF N/A
- CMPX N/A
- Revenue Next Year
- PSF N/A
- CMPX N/A
- P/E Ratio
- PSF N/A
- CMPX N/A
- Revenue Growth
- PSF N/A
- CMPX N/A
- 52 Week Low
- PSF $16.00
- CMPX $0.77
- 52 Week High
- PSF $20.19
- CMPX $4.08
- Technical
- Relative Strength Index (RSI)
- PSF 55.16
- CMPX 56.95
- Support Level
- PSF $19.10
- CMPX $2.02
- Resistance Level
- PSF $19.51
- CMPX $2.23
- Average True Range (ATR)
- PSF 0.16
- CMPX 0.12
- MACD
- PSF 0.00
- CMPX 0.02
- Stochastic Oscillator
- PSF 72.88
- CMPX 66.67
About PSF Cohen & Steers Select Preferred and Income Fund Inc.
Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.